Nectar Lifesciences Limited (NECLIFE.BO)
BSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹10.60 (+1.05%) as of
Key statistics
- Market cap
- 2.06B
- EPS (TTM)
- -2.08
- 52-week range
- 10.21 – 38.88
- Beta
- 0.33
- Revenue (TTM)
- 16.7B
- Profit margin
- -21.26%
- Volume
- 14.19k
About Nectar Lifesciences Limited
Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company offers menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Chandigarh, India
- Employees
- 1,786
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.